Top Markets
#1 Pleasing Gold Pleasing Gold +562.02%
#2 Islamic Coin Islamic Coin +154.23%
#3 PulseChain PulseChain +52.83%
#4 BOOK OF MEME BOOK OF MEME +49.57%
#5 DogBull DogBull +38.73%
#6 Nockchain Nockchain +25.73%
#7 ORDI ORDI +21.49%
#8 PondCoin PondCoin +21.01%
#9 rsERG rsERG +18.16%
#10 Monad Monad +17.83%
Coin of the day
Pleasing Gold Pleasing Gold
設定
言語
日本
通貨
USD
テーマ
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
株式のランク #27038
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
株価
$1.48
最終同期: 2023-05-31
時価総額
$35.54M
変化（1日）
-5.73%
変化（1年）
0.00%
国
US
取引 TCR2 Therapeutics Inc. (TCRR)

カテゴリー

Healthcare
TCR2 Therapeutics Inc.（TCRR）の収益
Aug 2026 時点の収益 TTM: 0
TCR2 Therapeutics Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
TCR2 Therapeutics Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH